Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma

Journal of Hepatology

Volumn 67, Issue 4, 2017, Pages 749-757

  Loosen, Sven H ^a   Roderburg, Christoph ^a   Kauertz, Katja L ^a   Pombeiro, Inês ^a   Leyh, Catherine ^a   Benz, Fabian ^a   Vucur, Mihael ^a   Longerich, Thomas ^a   Koch, Alexander ^a   Braunschweig, Till ^a   Ulmer, Tom F ^a   Heidenhain, Christoph ^a   Tacke, Frank ^a   Binnebösel, Marcel ^a   Schmeding, Maximilian ^b   Trautwein, Christian ^a   Neumann, Ulf P ^a   Luedde, Tom ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b KLINIKUM DORTMUND   (Germany)

Author keywords

Biomarker; CA19 9; Cancer; CCA; CEA; Osteopontin; Prognosis

Indexed keywords

OSTEOPONTIN; MESSENGER RNA; RNA; SPP1 PROTEIN, HUMAN; SPP1 PROTEIN, MOUSE; TUMOR MARKER;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER SURGERY; LIVER TISSUE; MALE; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL RATE; TUMOR LOCALIZATION; UPREGULATION; ANIMAL; BILE DUCT TUMOR; BLOOD; CASE CONTROL STUDY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BILE DUCT NEOPLASMS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 85025837630     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.06.020     Document Type: Article

References (44)

1. Bergquist, A., von Seth, E., Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 29 (2015), 221–232.
2. Shaib, Y., El-Serag, H.B., The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004), 115–125.
3. Razumilava, N., Gores, G.J., Cholangiocarcinoma. Lancet 383 (2014), 2168–2179.
4. Khan, S.A., Taylor-Robinson, S.D., Toledano, M.B., Beck, A., Elliott, P., Thomas, H.C., Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (2002), 806–813.
5. Patel, T., Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001), 1353–1357.
6. Mouzas, I.A., Dimoulios, P., Vlachonikolis, I.G., Skordilis, P., Zoras, O., Kouroumalis, E., Increasing incidence of cholangiocarcinoma in Crete 1992–2000. Anticancer Res 22 (2002), 3637–3641.
7. Bragazzi, M.C., Cardinale, V., Carpino, G., Venere, R., Semeraro, R., Gentile, R., et al. Cholangiocarcinoma: Epidemiology and risk factors. Transl Gastrointest Cancer 1 (2011), 21–32.
8. Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A., et al. Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer. N Engl J Med 362 (2010), 1273–1281.
9. Kang, M.J., Jang, J.-Y., Chang, J., Shin, Y.C., Lee, D., Kim, H.B., et al. Actual long-term survival outcome of 403 consecutive patients with hilar cholangiocarcinoma. World J Surg 40 (2016), 2451–2459.
10. Bi, C., Wang, L.M., An, S.L., Huang, J., Feng, R.M., Wu, F., Et al. (Trans.) Analysis of the survival of 123 patients with intrahepatic cholangiocarcinoma after surgical resection Zhonghua Zhong Liu Za Zhi 38 (2016), 466–471.
11. Buettner, S., Margonis, G.A., Kim, Y., Gani, F., Ethun, C.G., Poultsides, G., et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma. HPB 18 (2016), 510–517.
12. Subraman, V., Thiyagarajan, M., Malathi, N., Rajan, S.T., OPN-revisited. J Clin Diagn Res 9 (2015), Ze10–Ze13.
13. Anborgh, P.H., Mutrie, J.C., Tuck, A.B., Chambers, A.F., Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 5 (2011), 111–122.
14. Roderburg, C., Benz, F., Cardenas, D.V., Lutz, M., Hippe, H.-J., Luedde, T., et al. Persistently elevated osteopontin serum levels predict mortality in critically ill patients. Crit Care, 19, 2015, 271.
15. Imano, M., Satou, T., Itoh, T., Sakai, K., Ishimaru, E., Yasuda, A., et al. Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13 (2009), 1577–1582.
16. Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A.F., Szabo, M., et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94 (2002), 513–521.
17. Koopmann, J., Fedarko, N.S., Jain, A., Maitra, A., Iacobuzio-Donahue, C., Rahman, A., et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13 (2004), 487–491.
18. Lin, F., Li, Y., Cao, J., Fan, S., Wen, J., Zhu, G., et al. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep 38 (2011), 5205–5210.
19. Irby, R.B., McCarthy, S.M., Yeatman, T.J., Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 21 (2004), 515–523.
20. Chakraborty, G., Jain, S., Patil, T.V., Kundu, G.C., Down-regulation of osteopontin attenuates breast tumour progression in vivo. J Cell Mol Med 12 (2008), 2305–2318.
21. Cui, R., Takahashi, F., Ohashi, R., Gu, T., Yoshioka, M., Nishio, K., et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57 (2007), 302–310.
22. Hass, H.G., Nehls, O., Jobst, J., Frilling, A., Vogel, U., Kaiser, S., Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 14 (2008), 2501–2510.
23. Laohaviroj, M., Chamgramol, Y., Pairojkul, C., Mulvenna, J., Sripa, B., Clinicopathological significance of osteopontin in cholangiocarcinoma cases. Asian Pac J Cancer Prev 17 (2016), 201–205.
24. Sulpice, L., Rayar, M., Desille, M., Turlin, B., Fautrel, A., Boucher, E., et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 58 (2013), 1992–2000.
25. Terashi, T., Aishima, S., Taguchi, K., Asayama, Y., Sugimachi, K., Matsuura, S., et al. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int 24 (2004), 38–45.
26. Iguchi, T., Yamashita, N., Aishima, S., Kuroda, Y., Terashi, T., Sugimachi, K., et al. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncology 76 (2009), 293–300.
27. Poruk, K.E., Firpo, M.A., Scaife, C.L., Adler, D.G., Emerson, L.L., Boucher, K.M., et al. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42 (2013), 193–197.
28. Chimparlee, N., Chuaypen, N., Khlaiphuengsin, A., Pinjaroen, N., Payungporn, S., Poovorawan, Y., et al. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis b-related hepatocellular carcinoma. Asian Pac J Cancer Prev 16 (2015), 7211–7217.
29. Roderburg, C., Benz, F., Vargas Cardenas, D., Koch, A., Janssen, J., Vucur, M., et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int 35 (2015), 1172–1184.
30. Benz, F., Roderburg, C., Vargas Cardenas, D., Vucur, M., Gautheron, J., Koch, A., et al. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med, 45, 2013, e42.
31. Gürlevik, E., Fleischmann-Mundt, B., Armbrecht, N., Longerich, T., Woller, N., Kloos, A., et al. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Hepatology 58 (2013), 1031–1041.
32. Koch, A., Voigt, S., Kruschinski, C., Sanson, E., Dückers, H., Horn, A., et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care, 15, 2011, R63.
33. Desmet, V.J., Gerber, M., Hoofnagle, J.H., Manns, M., Scheuer, P.J., Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994), 1513–1520.
34. Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33 (2015), 550–558.
35. Patel, A.H., Harnois, D.M., Klee, G.G., LaRusso, N.F., Gores, G.J., The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000), 204–207.
36. Wang, B., Chen, L., Chang, H.-T., Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. Biomark Med, 2016, 10.2217/bmm-2015-0062.
37. Saito, H., Noji, T., Okamura, K., Tsuchikawa, T., Shichinohe, T., Hirano, S., A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery 159 (2016), 842–851.
38. Gerhardt, T., Milz, S., Schepke, M., Feldmann, G., Wolff, M., Sauerbruch, T., et al. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 12 (2006), 5495–5500.
39. Lin, Z.-Y., Liang, Z.-X., Zhuang, P.-L., Chen, J.-W., Cao, Y., Yan, L.-X., et al. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer, 16, 2016, 792.
40. Kumar, S., Sharma, P., Kumar, D., Chakraborty, G., Gorain, M., Kundu, G.C., Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One, 8, 2013, e69116.
41. Maeda, N., Ohashi, T., Chagan-Yasutan, H., Hattori, T., Takahashi, Y., Harigae, H., et al. Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia. Retrovirology, 12, 2015, 99.
42. Bandopadhyay, M., Bulbule, A., Butti, R., Chakraborty, G., Ghorpade, P., Ghosh, P., et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 18 (2014), 883–895.
43. Rittling, S.R., Matsumoto, H.N., McKee, M.D., Nanci, A., An, X.R., Novick, K.E., et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 13 (1998), 1101–1111.
44. Weber, G.F., The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8 (2011), 263–288.